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the NetherlandsThe most common variant causing Pompe disease is c.-32-
13T>G (IVS1) in the acid a-glucosidase (GAA) gene, which
weakens the splice acceptor of GAA exon 2 and induces partial
and complete exon 2 skipping. It also allows a low level of leaky
wild-type splicing, leading to a childhood/adult phenotype.
We hypothesized that cis-acting splicing motifs may exist that
could be blocked using antisense oligonucleotides (AONs) to
promote exon inclusion. To test this, a screen was performed
in patient-derived primary ﬁbroblasts using a tiling array of
U7 small nuclear RNA (snRNA)-based AONs. This resulted
in the identiﬁcation of a splicing regulatory element in GAA
intron 1. We designed phosphorodiamidate morpholino olig-
omer-based AONs to this element, and these promoted exon
2 inclusion and enhanced GAA enzyme activity to levels above
the disease threshold. These results indicate that the common
IVS1 GAA splicing variant in Pompe disease is subject to nega-
tive regulation, and inhibition of a splicing regulatory element
using AONs is able to restore canonical GAA splicing and
endogenous GAA enzyme activity.Received 29 October 2016; accepted 3 March 2017;
http://dx.doi.org/10.1016/j.omtn.2017.03.001.
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Pre-mRNA splicing is a highly regulated process, the outcome of
which is critical for homeostasis and disease. The diversity of splicing
variants positively correlates with evolutionary complexity, as it
allows for an expansion of the possible protein isoforms that are
derived from the same genetic information.1 The regulation of
splicing is still relatively poorly understood, which is caused by the
many factors that can affect splicing outcome. At the level of RNA
sequences, splicing regulatory elements are loosely deﬁned. The
splice site junctions, as well as the polypyrimidine (pY) tract and
branch point, are relatively easy to identify. Splice regulatory ele-
ments exist, including the exonic and intronic splice enhancer and
silencer elements (ESEs, ESSs, ISEs, and ISSs, respectively), but these
are more difﬁcult to predict.2 The expression levels of splicing regu-
latory proteins can also play an important role in splicing outcome.3
Furthermore, the speed of RNA polymerase II transcription is
thought to affect splicing efﬁciency, because splicing mainly occurs
co-transcriptionally, and the available splice sites that are present90 Molecular Therapy: Nucleic Acids Vol. 7 June 2017 ª 2017 The Auth
This is an open access article under the CC BY-NC-ND license (http://in the protruding pre-mRNA within a certain time frame compete
for the splicing machinery.4,5 Additional levels of regulation are
chromatin modiﬁcations and the composition of the UTRs.6,7
All together, these diverse levels of regulation highlight the require-
ment for experimental testing of alternative splicing to validate
predictions.
Disruption of splicing has been documented in a large number of
human disorders. Approximately 9% of pathogenic variants anno-
tated in the Human Gene Mutation Database are linked to splicing
defects (http://www.hgmd.cf.ac.uk/). In this database, variants that
affect splicing predominantly concern those that are located at splice
site junctions.8 This is caused by the inherent detection bias for
these variants, which are mostly identiﬁed using splice prediction
algorithms. However, variants can also alter splicing by the genera-
tion of new splice sites9,10 or by disturbing or generating other splice
regulatory elements.11,12 In addition, variants in the coding region
can have more than one effect (i.e., a missense variant can also
have an effect on splicing).9 Furthermore, indirect effects on target
genes are known (e.g., in response to mutations in master splicing
factors such as the muscleblind family, SF3B1, and U2AF35).13,14
The consequences of such events can be diverse and may include
(partial) exon skipping and/or (partial) intron retention. The ﬁnal
mRNA may be in frame, which in certain cases may result in a
protein product that retains some biological activity. A reading
frameshift usually results in mRNA decay and absence of a protein
product, although the extent at which decay occurs may vary. It is
likely that many more pathogenic splicing variants exist that are
located outside the region of canonical splice sites, and that the
percentage of identiﬁed variants that affect splicing will increase
in the future.or(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.orgAntisense oligonucleotides (AONs) can modulate splicing by binding
to the pre-mRNA and blocking splicing regulatory sequences. One
type of AONhas beenmodiﬁed from the naturally occurringU7 small
nuclear RNA (snRNA), which is normally utilized in histone pre-
mRNA processing but has been modiﬁed to target the pre-mRNA
of choice.15 U7 snRNA-based AONs are stabilized by a stem loop
and also contain an antisense sequence that is used for targeting.16
Another strategy is the use of chemically modiﬁed AONs that
are capable to bind to RNA via Watson-Crick base pairing but are
insensitive to RNase-mediated degradation due to their modiﬁed
backbone chemistry. Various backbones with different properties
are known, which include phosphorodiamidate morpholino oligomer
(PMO), 20-O-methyl phosphorothioate, 2-O-methoxyethyl phos-
phorothioate, and tricyclo-DNA modiﬁcations.17
A straightforward approach to modulate splicing using AONs is to
block a splice junction. This will result in exon skipping, which can
be advantageous, for example, to bypass a mutation hotspot and to
restore the reading frame. This will only workwhen the resulting trun-
cated protein is at least partially active, which is the case for the dys-
trophin protein, providing a potential therapy forDuchennemuscular
dystrophy.18,19 This approach has been tested inmultiple clinical trials
and has moved forward toward conditional approval by the US Food
and Drug Administration (FDA).20 Many other examples have been
published, in which a cryptic splice site is blocked with an AON to
restore canonical splicing (reviewed in Havens and Hastings17). We
recently showed that this is possible in the case of GAA variants
that cause Pompe disease.9 Restoration of splicing becomesmore chal-
lenging in cases where a splicing variant causes exon skipping and re-
quires promotion of exon inclusion. When there is no clear cryptic
splice site involved that can be blocked by an AON, such cases require
the identiﬁcation of ISS or ESS elements that are critical for exon in-
clusion. Blocking of these splice silencers with an AON may in turn
promote exon inclusion. Few examples for promotion of exon inclu-
sion exist; notably, for spinal muscular atrophy, caused by variants in
the SMN1 gene, AONs have been designed that reactivate the nor-
mally silent sister gene SMN2. SMN2 contains an exonic variant
that causes exon skipping, and AONs have been identiﬁed that block
ESS or ISS sequences and promote exon inclusion.21,22 One of these,
which targets the ISS, is currently being tested in clinical trials.23
Because AONs are sequence speciﬁc, they are usually only suitable
for a subgroup of patients with similar gene variants. In Pompe dis-
ease, a common splicing variant occurs in the majority of Caucasian
patients with the childhood/adult form. This well-described variant,
c.-32-13T>G (also known as IVS1, or r.-32-13u>g at the RNA level),
is located in the pY tract of exon 2 of the acid a-glucosidase (GAA)
pre-mRNA and causes weakening of the splice acceptor site, resulting
in complete or partial skipping of exon 2.24–27 This exon contains the
translation start codon, and its skipping results in mRNA degradation
and a subsequent reduction of GAA protein production. Approxi-
mately 10%–15% of transcripts are spliced normally and produce a
low level of wild-type GAA protein, which explains why these patients
develop the childhood/adult form of Pompe disease. A minimumGAA activity of 20% of the average healthy control values is required
to prevent the disease.28 The restoration of splicing from the IVS1
variant using AONs would potentially provide a therapeutic option
for the majority of Caucasian patients with Pompe disease. This
may be beneﬁcial in addition to or instead of the current enzyme
replacement therapy, which has a partial and heterogeneous response
and is extremely expensive. However, splicing correction from the
IVS1 variant requires promotion of exon inclusion, and no negatively
acting splicing regulatory sequences in the GAA gene that are
amenable to inhibition using AONs are currently known.
Here, we used a screen to modulate endogenous GAA splicing using
U7 snRNA-based AONs expressed via lentiviral transduction in
patient-derived primary ﬁbroblasts. This resulted in the identiﬁcation
of cis-acting splicing regulatory elements that were subsequently
tested using PMO-based AONs. Two overlapping AONs were identi-
ﬁed that promoted inclusion of exon 2 in cells from patients carrying
the IVS1 variant. In cells from healthy controls, the AONs did not
change GAA splicing or expression, conﬁrming that they acted on
splicing rather than elevating total GAA transcript levels. The
AONs increased GAA enzymatic activity in patient-derived cells to
above the disease threshold of 20%. These ﬁndings demonstrate the
feasibility to correct aberrant splicing from the common IVS1 GAA
variant by blocking a negative splicing element to promote exon
inclusion.
RESULTS
Aberrant Splicing of GAA Pre-mRNA in the Presence of the IVS1
Variant
Previous work resulted in the characterization of aberrant splicing
caused by the IVS1 GAA variant.24–27 Splicing products include wild-
typeGAAmRNA (N) caused by leaky normal splicing, partial skipping
of exon 2 caused by utilization of a cryptic splice site in exon 2 (SV3),
and full skipping of exon 2 (SV2). These products can be identiﬁed by
ﬂanking exonRT-PCR in primaryﬁbroblasts using primers that anneal
to exons 1 and 3 (Figure 1A). Splicing is subject to regulation by addi-
tional cis-acting RNA sequences besides the sequences surrounding the
canonical splice sites. These include ESSs, ISSs, ESEs, and ISEs and can
be located distant from canonical splice sites (hypothetical example
given in Figure 1B). Approximately 10%–15% of the GAA pre-
mRNA is correctly spliced, indicating that the pathogenic effect of
the IVS1 variant is not fully detrimental to splicing of GAA exon 2.
We hypothesized that it may be possible to promote exon 2 inclusion
by inhibition of a splicing negatively acting splicing regulatory element
using an AON. To test this, in silico prediction was performed using
several algorithms, which resulted in a plethora of splicing regulatory
elements (Figure 1C). However, the results were algorithm dependent
and many predicted enhancer and silencer sequences overlapped
without indicating an obvious candidate silencer element that could
be amenable to inhibition by an AON.
Identification of Repressors of GAA Exon 2 Inclusion
To identify splicing regulatory elements experimentally, an unbiased
screen was performed using a non-overlapping tiling array of AONsMolecular Therapy: Nucleic Acids Vol. 7 June 2017 91
Figure 1. In Silico Prediction to Identify Splicing Regulatory Elements Surrounding the IVS1 Variant
(A) Outline of the three major splicing products of the GAA pre-mRNA caused by the IVS1 variant in a patient-derived primary fibroblast. The gel illustrates the results of
flanking exon RT-PCR analysis of GAA exon 2 using primers that anneal to exon 1 and exon 3. Loading from left to right is as follows: DNA size markers (in basepairs); WT
indicates control fibroblasts and IVS1 denotes fibroblasts from patient 1. Cartoons of pre-mRNAs illustrate splicing events as described.24–27 The location of the r.-32-13u>g
(IVS1) variant in the pY tract is indicated. Spliced mRNA cartoons are shown on the far right. (B) Cartoon showing hypothetical splicing regulatory elements that may be
subject to modulation (e.g., by a U7 snRNA). (C) In silico prediction in Human Splicing Finder 3.0 (http://www.umd.be/HSF3/) of exonic and intronic splicing silencers
surrounding the GAA IVS1 variant. Algorithms used are indicated below the graph. PESE, putative exonic splicing enhancers; PESS, putative exonic splicing silencers.
Molecular Therapy: Nucleic Acidsthat cover part of intron 1 and the complete exon 2 of the GAA pre-
mRNA (Figure 2A). Because of the high costs involved when testing a
large series of chemically modiﬁed AONs, AONs were expressed as
U7 snRNAs using a lentiviral vector. The original U7 snRNA vector
was adapted to enable one-step cloning of an AON and intermediate
throughput screening (Figure S1A).29 To validate the U7 snRNA vec-
tor, a control experiment was performed on primary ﬁbroblasts92 Molecular Therapy: Nucleic Acids Vol. 7 June 2017derived from a patient with adult Pompe disease (patient 1), who
carried the IVS1 variant on one allele and the c.525delT on the second
allele. A U7 snRNA-based AON was targeted to the splice sites of
exon 4 of cyclophilin A (CypA) pre-mRNA (Figure S1B). This AON
was capable of inducing skipping of exon 4, as shown by ﬂanking
exon RT-PCR (Figure S1C) and exon internal qRT-PCR analysis
(Figure S1D). This conﬁrmed previous reports29 and demonstrated
Figure 2. U7 snRNA Screen to Identify Splicing Regulatory Elements Involved in GAA Exon 2 Splicing
(A) Locations of U7 snRNA-based AONs generated for the screen in (B). (B) Screen to identify splicing regulatory elements that negatively regulate splicing of GAA exon 2.
Primary fibroblasts from patient 1 (IVS1, c.525delT) were transduced with U7 snRNA-expressing lentiviruses (200 ng p24 protein as determined by ELISA). The effects on
GAA exon 2 expression were measured using qRT-PCR (black line;GAA [N] expression; primers are indicated in the upper left cartoon). Effects on GAA enzymatic activity are
indicated by the red line. The cartoon of GAA pre-mRNA below the graph indicates the positions of the AONs tested. Data are expressed relative to non-transduced (NT)
fibroblasts and represent means ± SD of three biological replicates. Samples were normalized for b-Actin expression. (C) The experiment in (B) was also analyzed by flanking
exon RT-PCR of GAA exon 2. b-Actin mRNA was used as loading control. Primers are indicated in the upper left cartoon. (n = 3).
www.moleculartherapy.orgthat the modiﬁed U7 snRNA construct can be used to modulate
splicing. Subsequently, the U7 snRNA screen using the AONs indi-
cated in Figure 2A was performed on ﬁbroblasts from patient 1.
The screen resulted in the identiﬁcation of a number of U7 snRNA-
based AONs that modulated inclusion of exon 2 in the GAA
mRNA, as shown with qRT-PCR analysis (Figure 2B, black line).
Importantly, only mRNA from the allele carrying the IVS1 variant
was detected due to the frameshift induced by the c.525delT variant
on the second allele, which results in mRNA degradation. Notably,
U7 snRNAs targeting two regions in intron 1, at c.-32-179 and
c.-32-219, promoted inclusion of GAA exon 2. Exclusion of exon 2
was promoted by U7 snRNAs that targeted regions in the 50 part of
exon 2. Similar results were obtained using ﬂanking exon RT-PCR
analysis (Figure 2C). Promotion and inhibition of exon 2 inclusionresulted in increased and decreased GAA enzymatic activity, respec-
tively (Figure 2B, compare black and red lines).
Next, the effect of the lentiviral amount was tested using p24 ELISA;
200 ng yielded an optimal ratio between biological effect and
nonspeciﬁc reduction of cell viability and GAA expression seen at
high viral amounts (Figure S2). To ﬁne-tune the optimal location
of U7 snRNAs targeting c.-32-179 and c.-32-219, a microwalk was
performed around these regions with U7 snRNAs that shifted
2 nt (Figure 3A). This showed that the locations identiﬁed using
the initial U7 snRNA screen were peak values. In addition, the
microwalk revealed two nearby locations at c.-32-183 and c.-32-
185 whose inhibition promoted exon 2 inclusion (Figures 3B and
3C). Taken together, the U7-based snRNA screen of intron 1 andMolecular Therapy: Nucleic Acids Vol. 7 June 2017 93
Figure 3. U7 snRNA-Based Miniscreen of Targets Identified with the Large Screen
(A) Two hits from the screen shown in Figures 2B and 2C (in bold) were further tested in amicrowalk using theU7 snRNA system. Primer locations are indicated in the cartoon.
(B) Results of the microwalk, as analyzed by qRT-PCR. (C) As in (B), using RT-PCR analysis. Results are expressed relative to non-transduced fibroblasts and represent
means ± SD of three biological replicates.
Molecular Therapy: Nucleic Acidsexon 2 identiﬁed regions potentially involved in repression of GAA
exon 2 inclusion.
Blockage of Splicing Repressor Sequences Using Antisense
Oligonucleotides
To test whether morpholino-based AONs can modulate aberrant
splicing caused by the IVS1 variant, AONs were designed based
on the results from the U7 snRNA screen shown in Figure 3. Spe-
ciﬁc requirements of low G content on chemical synthesis posed
constrains to the regions that could be targeted but it was possible
to design AONs that targeted the two major putative repressor se-
quences at c.-32-219 (AONs 1 and 2) and c.-32-179 (AONs 3
and 4) (Figures 4A and S3A). To test whether primary ﬁbroblasts
were amenable to splicing modulation using morpholino-based
AONs, AONs targeting CypA were used as positive control. Two94 Molecular Therapy: Nucleic Acids Vol. 7 June 2017PMO-based AONs that target the 30 donor splice site of exon 4
in the CypA pre-mRNA (Figures S3A and S3B) were able to pro-
mote skipping of exon 4 and exons 3 and 4 after transfection into
primary ﬁbroblasts, as shown by ﬂanking exon RT-PCR and qRT-
PCR analysis (Figures S3C and S3D), which is in agreement with
our previous report.9 Next, AONs 1–4 targeting the identiﬁed re-
gions in the GAA pre-mRNA were tested by transfecting primary
ﬁbroblasts from patient 1. qRT-PCR analysis of exon 2 inclusion
showed that AONs 3 and 4 promoted exon 2 inclusion more than
2-fold, whereas AONs 1 and 2 were ineffective (Figure 4B).
Concomitant effects on GAA enzymatic activity were found, with
more than 2-fold enhancement by AONs 3 and 4, while AONs 1
and 2 had no effect. This showed that PMO-based AONs that tar-
geted the region of c.-32-179 promoted exon 2 inclusion, and that
other PMO-based AONs tested were ineffective.
(legend on next page)
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Molecular Therapy: Nucleic AcidsNext, the concentration-dependent effects of AONs 3 and 4 were
tested after transfection in ﬁbroblasts from patient 1 (Figures 4C
and 4D). AONs 3 and 4 induced a concentration-dependent increase
in both the expression of full-length GAA transcript and GAA enzy-
matic activity. Effects were almost maximal at 2 mM AON and
reached a maximum at 5–20 mM. These results were conﬁrmed in a
ﬁbroblast cell line from patient 2 (Figures 4E and 4F). This patient
(genotype IVS1/c.923A>C) contained a missense GAA variant on
allele 2, which was expressed at the mRNA level and led to a high
“background” GAA cDNA level in the RT-PCR assays. We conclude
that AONs 3 and 4 show in vitro activities that are sufﬁcient to elevate
canonical GAA pre-mRNA splicing, and thus GAA enzymatic activ-
ity, to above the disease threshold of 20% of the average level present
in healthy controls that has been established in the diagnostic depart-
ment of our center.
To conﬁrm the mechanism by which AON 3 and 4 enhanced GAA
enzymatic activity (i.e., by modulating splicing rather than total
gene expression), analysis of individual splicing products was per-
formed. Of note, full-skip (SV2) and cryptic splicing transcripts
(SV3) lack the translation start codon and are subject to mRNA
degradation, hampering accurate relative quantiﬁcation. The effect
of AON 4 was tested in control ﬁbroblasts and in ﬁbroblast from
patients 1 and 2. Semiquantitative RT-PCR analysis using primers
annealing to exon 1 and exon 3 showed that in patients with
IVS1, AON 4 treatment caused an increase in the amount of the
full-length (N) transcript, while the amount of the full-skip (SV2)
transcript was reduced (Figure 4G). The amount of cryptic splicing
transcript SV3 remained unchanged. AON 4 had no effect on GAA
expression in control cells. Quantitative analysis by qRT-PCR uti-
lized splicing product-speciﬁc primers,27 and this conﬁrmed the
semiquantitative analysis (Figure 4H). These results suggest that
AON 4 enhances expression of wild-type GAA mRNA by promot-
ing exon 2 inclusion during aberrant splicing caused by the IVS1
variant, rather than acting on enhancing total GAA gene expression.
This is further supported by the lack of effect on GAA expression in
control cells.
DISCUSSION
The purpose of this work was to test whether aberrant GAA splicing
caused by the common IVS1 variant could be restored using AONs.
To this end, we performed a lentiviral U7 snRNA-based screen withFigure 4. Splicing Correction of GAA Exon 2 Using PMO-Based AONs
(A) Positions in the GAA pre-mRNA to which PMO-based AONs1–4 anneal. (B) Effect
measured using qRT-PCR analysis (GAA [N] mRNA level) and GAA enzymatic activity
pressed relative to the average levels in healthy control fibroblasts and were corrected fo
As in (B) but now using a concentration range of AON 4. (E) As in (C) but now with the tr
fibroblasts. (G) Flanking exon RT-PCR analysis of the effect of AON 4 onGAA exon 2 inc
analysis of individual splicing products ofGAA exon 2 splicing. The N, SV2, and SV3 prod
on GAA exon 2 splicing was determined in fibroblasts from patients 1 and 2 and contro
expression in untreated cells to visualize the effect per variant. Note that patient 2 carrie
expressed from this allele, which partially masks the effect onmRNA expression from the
presence of a variant that causes a frame shift and subsequent mRNA degradation. Dat
96 Molecular Therapy: Nucleic Acids Vol. 7 June 2017the aim to identify splicing regulatory sequences that could be
blocked to promote exon inclusion. Hits from this screen were
tested using PMO-based AONs. Two AONs were identiﬁed that
promoted exon inclusion and GAA enzyme activity to above the
disease threshold of 20% of average healthy control levels. These re-
sults identify splicing regulatory elements that negatively regulate
the IVS1 variant, and they provide proof of concept for the
restoration of canonical splicing in cells from patients with Pompe
disease.
The IVS1 GAA variant represented a challenging case, because it is
located in the pY tract of exon 2 and weakens the recognition of the
splice acceptor site of exon 2. It was not obvious whether it was
possible to enhance exon inclusion using AONs, as no negative
splice regulatory elements in the GAA gene have been described
that could be amenable to inhibition using an AON. This contrasts
with other, more rare, GAA variants that affect splicing by causing a
major shift from canonical toward cryptic splicing. In these cases,
AONs that prevent cryptic splicing could restore canonical splicing.9
We were encouraged by the observation that the IVS1 variant also
allows a low level of leaky wild-type splicing, indicating that canon-
ical splicing was still possible and that the pY tract was still partially
functional. Previous ﬁndings that small drugs could enhance exon 2
splicing strengthen this hypothesis.26 We identiﬁed a splicing regu-
latory element in intron 1 that was located approximately 280 nt
upstream of the canonical splice acceptor of GAA exon 2. In an
accompanying work,30 we show that this does not concern a
classical ISS motif, but that it is the pY tract of a cryptic splice
acceptor site that, together with a downstream splice donor, forms
a pseudo exon.
Current prediction programs for the identiﬁcation of cis-acting ele-
ments that modulate splicing outcome vary widely in outcome, as
illustrated in Figure 1C. We therefore performed an unbiased screen
using U7 snRNA-based AONs modiﬁed from Liu et al.16,29 The len-
tiviral vector employed here was modiﬁed to enable one-step cloning
with a >90% success rate. Lentiviral transduction showed near 100%
infection of target cells, ensuring expression of the U7 snRNAs in all
target cells (data not shown). An alternative approach would be to
order all desired AONs and to transfect directly in target cells, but
this is expensive and not feasible for most research laboratories.
The U7 snRNA-based approach identiﬁed splicing regulatory motifsof AONs1–4 in fibroblasts from patient 1. GAA exon 2 inclusion in the mRNA was
using 4-methylumbelliferyla-D-glucopyranoside (4-MU) as substrate. Data are ex-
r b-Actin expression. (C) As in (B) but now using a concentration range of AON 3. (D)
eatment of patient 2 fibroblasts. (F) As in (D) but now with the treatment of patient 2
lusion in fibroblasts from patient 1 and 2., 0 mMAON; +, 20 mMAON. (H) qRT-PCR
ucts were quantified using primers as outlined in the cartoon, and the effect of AON 4
l 1. Data are corrected for b-Actin expression and normalized per splicing variant for
d a pathogenic missense GAA variant on the second allele. GAA mRNA is normally
IVS1 allele. Patient 1 has noGAAmRNA expression from the second allele due to the
a are means ± SDs of three biological replicates. *p < 0.05; **p < 0.01; ***p < 0.001.
www.moleculartherapy.orgthat both reduce (intron 1) and enhance (50 part of exon 2) inclusion
of GAA exon 2 (Figure 2B). We were unable to identify these
sequences using currently available splicing prediction programs,31
highlighting the need for experimental work. This approach should
be more generally applicable to unravel basic mechanisms of splicing
and to identify therapeutic targets for splicing variants in human
disease.
Metabolic disorders such as Pompe disease are good candidates for
AON-mediated splicing correction. Often the enzyme deﬁciency
only needs elevation to levels above a threshold to be fully func-
tional.32–34 Hits from the U7 snRNA screen were tested using
PMO-based AONs, and these promoted exon inclusion and GAA
enzyme activity to above the disease threshold of 20%. This threshold
was evident from the evaluation of ﬁbroblast samples (using 4-MU as
substrate) from 700 individuals in our center, 350 of which were
diagnosed with Pompe disease based on clinical examination, muscle
pathology, and biochemical and DNA analysis. While GAA enzyme
activity levels in patients never exceeded 20%, the level in healthy
individuals ranged from 40% to 180%.We note that the GAA enzyme
activity assay is very sensitive to cell culture and assay conditions, and
different patient and normal ranges (and therefore disease thresholds)
may apply depending on the diagnostic center. Usually the IVS1
variant is present in combination with a variant on the second allele
with no residual enzymatic activity, causing childhood/adult Pompe
disease, although homozygosity of the IVS1 variant has been
described in some patients with Pompe disease.35,36 Full restoration
of the IVS1 allele in compound heterozygous patients would provide
a maximum of 50% GAA activity relative to the average levels in
healthy controls, and this activity is within the range of healthy
controls.
These results form a proof of concept for the development of a poten-
tial alternative treatment of a large percentage of Caucasian patients
with Pompe disease. Current enzyme replacement therapy has limita-
tions and is based on intravenous delivery of rhGAA that is taken up
by target cells via mannose-6-phosphate receptor-mediated endocy-
tosis. AON-mediated splicing correction presents a different strategy,
as it enhances endogenous production of wild-type GAA enzyme.
Further work is required to test the potential of the identiﬁed
AONs for clinical implementation. The ﬁrst step is to test AONs in
the relevant cell type, skeletal muscle cells, as splicing can be cell-
type speciﬁc.37 This is described in our accompanying work.30
Another aspect is cellular uptake by skeletal muscle in vivo following
systemic delivery. AON treatments are well tolerated without
serious adverse events, as shown in phase I and II clinical trials using
20-O-methoxyethyl phosphorothioate and PMO chemistries for spi-
nal muscular atrophy and Duchenne muscular dystrophy, respec-
tively.23,38 This may accelerate testing of AONs for the treatment of
Pompe disease in a clinical setting. The ongoing development of
improved methods for AON delivery, including tricyclo-DNA-based
backbones39 and cell-penetrating peptides like Pip6A,40 is expected to
be relevant for the future testing of AON-based drugs for the treat-
ment of Pompe disease.MATERIALS AND METHODS
Obtaining Patient Fibroblasts
Dermal ﬁbroblasts from one control (control 1) and two patients
(patients 1 and 2) with Pompe disease were obtained via skin biopsy
with informed consent. The Erasmus Medical Center (MC) institu-
tional review board approved the study protocol. All patient and
control primary cell lines were negative for HIV, hepatitis B, and
hepatitis C as tested by qPCR analysis at the diagnostic Depart-
ment of Virology of the Erasmus MC Rotterdam. Both patient cell
lines contain the IVS1 mutation on one allele. The second allele
was c.525delT for patient 1 and c.923A>C (his>pro) for patient 2,
which both are established pathogenic GAA variants (www.
pompecenter.nl).
Nomenclature
Indications to variants and/or locations on the cDNA or (pre-)mRNA
conform to Human Genome Variation Society (HGVS) standards
(http://www.hgvs.org/mutnomen/).41
Modification of the U7 snRNA Vector for Efficient One-Step
Cloning of AON Sequences
The U7 snRNA gene and promoter were ampliﬁed by PCR from
female mouse genomic DNA using Fw-ms-U7 snRNA-Pst1 and
rv-ms-U7 snRNA-SalI primers, which included PstI and SalI over-
hang restriction sites. The PCR fragment (425 bp) was cloned into
a pCRII-TOPO vector according to the manufacturer’s manual (Invi-
trogen). SMopt and NsiI sites were generated by site-directed muta-
genesis according to an inner and outer primer design with Fw-
and Rv-U7 snRNA-SMopt or Fw- and Rv-U7 snRNA-NsiI as inner
primers and with Fw-M13 and Rv-M13 as outer primers (Table
S1), and they were subcloned using the PstI and SalI sites upstream
of the polypurine tract fragment of the lentiviral vector used for re-
programming, fromwhich OSKM and the spleen focus-forming virus
(SF) promoter were removed.Cloning of AONs into the U7 snRNA Vector
AONs were inserted via PCR ampliﬁcation using a forward primer
that contained the desired antisense sequence and the unique NsiI re-
striction site and the reverse primer Rv-ms- U7 snRNA-SalI. The
ampliﬁed PCR product was puriﬁed by agarose gel electrophorese, ex-
tracted using the gel extraction kit (QIAGEN), digested with NsiI and
SalI, puriﬁed with a PCR puriﬁcation kit from (QIAGEN), and cloned
into the NsiI and SalI sites of the U7 snRNA vector. Clones were veri-
ﬁed by sequencing with the Fw-ms-U7 snRNA-PstI (Table S1) and re-
striction enzyme digestion.
Cell Culture
Both HEK293T cells and human primary ﬁbroblasts were cultured in
high-glucose DMEM (Gibco) supplemented with 100 U/mL peni-
cillin/streptomycin/glutamine (Gibco/Thermo Scientiﬁc) and 10%
fetal bovine serum (Hyclone/Thermo Scientiﬁc). Cells were passaged
after reaching 80%/90% conﬂuence with TrypLE (Gibco/Thermo Sci-
entiﬁc). All cell lines were routinely tested for mycoplasma infectionMolecular Therapy: Nucleic Acids Vol. 7 June 2017 97
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negative.
Virus Production
Lentiviruses were produced by co-transfecting HEK293T cells at 80%
conﬂuence in a 10-cm culture dish with the lentivirus transfer vector
(3 mg SF-U7 snRNA vectors) and packaging plasmids (2 mg psPAX2
and 1 mg pVSV vectors) using Fugene 6 transfection according to the
manufacturer’s protocol (Promega). Lentiviruses were harvested
from the medium after 72 hr of transfection and were ﬁltered using
a 0.45-mm polyvinylidene ﬂuoride (PVDF) ﬁlter (Millipore). After
ﬁltering, lentiviruses were concentrated by high-speed centrifugation
for 2 hr at 20,000 rpm in a Beckman Coulter Ultracentrifuge with a
SW32 Ti rotor at 4C. The supernatant was removed and the pellet
was resuspended in 25 mL low-glucose DMEM (Invitrogen) per plate.
The virus was stored in aliquots at 80C.
p24 ELISA
Viral titers were determined with the HIV-1 p24 antigen ELISA kit
(Retrotek; Zeptomix) according to the manufacturer’s manual. Each
virus was diluted 1:400,000 and 1:1,000,000 and the optical density
at 450 nm (OD450) was measured with the Varioskan reader (Thermo
Scientiﬁc).
Transduction of U7 snRNA Vectors
One day before infection, 6  104 cells per single well of a 12-well
plate of primary ﬁbroblasts derived from patient 1 were seeded.
One day later, the cells were infected with 200 ng virus containing
the SF-U7 snRNA constructs; after 24 hr, cells were washed three
times with PBS before fresh medium was added. After 4 days, cells
were washed with PBS and harvested with RLT buffer from the
RNAeasy kit for RNA isolation (QIAGEN). For the GAA enzyme
activity assay, cells were harvested after 12 days.
Morpholino Transfections
Fibroblasts were transfected with morpholino AONs using Endo-
porter reagent (Gene-Tools). Cells were grown to 90% conﬂuence
before transfection. Endoporter reagent was used at a concentration
of 4.5 mL/mL medium. Morpholinos were dissolved in sterile water
to a concentration of 1 mM and the appropriate volume was added
to each culture well. Cells were harvested 3–5 days after AON
addition.
RNA Isolation and cDNA Synthesis
RNA was extracted with the RNeasy Mini Kit with DNase treatment
(QIAGEN) and was stored at80C in RNase-free water. cDNA was
synthesized from 500 ng RNA using the iScript cDNA synthesis kit
(Bio-Rad).
qRT-PCR
cDNA was diluted 5, 10, or 20 times and used with 7.5 mL iTaq Uni-
versal SYBRGreen Supermix (Bio-Rad) with 10 pmol/mL forward and
reverse primers (Table S1) in a CFX96 real-time system (Bio-Rad).
Cycle threshold (Ct) values were related to amounts using standard98 Molecular Therapy: Nucleic Acids Vol. 7 June 2017curves of four to six dilutions. Quantiﬁcation of expression was calcu-
lated relative to b-Actin expression.
Flanking Exon RT-PCR of GAA
cDNA (diluted 10 times) with GC GAA exon 1–3 fw and GC GAA
exon 1–3 rv primers (Table S1) were used for RT-PCR with the
Advantage GC 2 PCR kit (Clontech/Takara) and a GC-melt concen-
tration of 0.5 M according to the manufacturer’s protocol. The whole
GC-PCR reaction was analyzed on a 1.5% agarose gel containing
0.5 mg/mL ethidium bromide (Sigma-Aldrich).
GAA Enzyme Activity Assay
Cells were harvested with ice-cold lysis buffer (50 mM Tris, pH 7.5,
100mMNaCl, 50mMNaF, 1% Triton X-100, and one tablet of Roche
cOmplete Protease Inhibitor Cocktail, with EDTA) and incubated for
10 min on ice. Samples were centrifuged at 14,000 rpm for 10 min at
4C. GAA enzyme activity was measured using 4-MU (Sigma-
Aldrich) as substrate as described.27 Total protein concentration
was determined using a BCA protein assay kit (Pierce/Thermo
Scientiﬁc).
Because GAA enzyme activity data strongly depend on assay condi-
tions and so we could evaluate enzyme activities relative to the disease
threshold, we normalized the data based on two criteria: (1) the
enzyme activity of patient cells measured in a diagnostic setting rather
than a research setting, and (2) the average enzyme activity present in
healthy control ﬁbroblasts. These results, expressed as the percent of
control, are presented in Figure 4. Enzyme data without normaliza-
tion are shown in Figure S4.
Statistical Analysis
All data represent means ± SD, and p values refer to two-sided Stu-
dent’s t tests. The Bonferroni multiple testing correction was applied
where necessary. A p value < 0.05 was considered signiﬁcant. Data
showed normal variance. There was no power calculation in any of
the experiments. No randomization method was used. No samples
were excluded from the analyses. Investigators were not blinded to
the identity of the samples.
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